These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 10853135)
1. Three-dimensional conformal radiotherapy for early stage prostatic cancer: techniques, outcomes, and possible pitfalls. Dipetrillo TA Surg Oncol Clin N Am; 2000 Jul; 9(3):435-53, viii. PubMed ID: 10853135 [TBL] [Abstract][Full Text] [Related]
2. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Luxton G; Hancock SL; Boyer AL Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924 [TBL] [Abstract][Full Text] [Related]
3. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio. Hille A; Töws N; Schmidberger H; Hess CF Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789 [TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444 [TBL] [Abstract][Full Text] [Related]
5. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Mock U; Bogner J; Georg D; Auberger T; Pötter R Strahlenther Onkol; 2005 Jul; 181(7):448-55. PubMed ID: 15995838 [TBL] [Abstract][Full Text] [Related]
6. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy. Dörr W; Jaal J; Zips D Strahlenther Onkol; 2007 Dec; 183 Spec No 2():14-5. PubMed ID: 18166999 [No Abstract] [Full Text] [Related]
8. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471 [TBL] [Abstract][Full Text] [Related]
9. Dose-escalated 3D conformal radiotherapy in prostate cancer. Malone S Expert Rev Anticancer Ther; 2004 Aug; 4(4):663-8. PubMed ID: 15270669 [TBL] [Abstract][Full Text] [Related]
10. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer. Hanssen S; Norum J Anticancer Res; 2008; 28(5B):2865-8. PubMed ID: 19031926 [TBL] [Abstract][Full Text] [Related]
11. The comparison of radiotherapy techniques for treatment of the prostate cancer: the three-field vs. the four-field. Milecki P; Piotrowski T; Dymnicka M Neoplasma; 2004; 51(1):64-9. PubMed ID: 15004663 [TBL] [Abstract][Full Text] [Related]
12. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582 [TBL] [Abstract][Full Text] [Related]
13. Technological advances in radiotherapy for the treatment of localised prostate cancer. Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957 [TBL] [Abstract][Full Text] [Related]
14. [Acute toxicity in 50 patients with prostate cancer treated with conformal radiation therapy]. Nasr E; Merhej S; Nehme Nasr D; Fares G J Med Liban; 2001; 49(6):325-8. PubMed ID: 12744634 [TBL] [Abstract][Full Text] [Related]
15. Low-grade toxicity after conformal radiation therapy for prostate cancer--impact of bladder volume. Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Eble MJ Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):835-41. PubMed ID: 16289911 [TBL] [Abstract][Full Text] [Related]
16. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526 [TBL] [Abstract][Full Text] [Related]
17. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. Leborgne F; Fowler J Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194 [TBL] [Abstract][Full Text] [Related]
18. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective. Parker W; Patrocinio H Can J Urol; 2005 Jun; 12 Suppl 2():48-52. PubMed ID: 16018834 [TBL] [Abstract][Full Text] [Related]
19. Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: comparison of two treatment techniques (six coplanar fields and two dynamic arcs). Jereczek-Fossa BA; Cattani F; D'Onofrio A; Cambria R; Kowalczyk A; Corallo A; Vavassori A; Zerini D; Ivaldi GB; DeCobelli O; Orecchia R Radiother Oncol; 2006 Dec; 81(3):294-302. PubMed ID: 17113670 [TBL] [Abstract][Full Text] [Related]
20. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]